Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
GEVA's Cash to Debt is ranked higher than
81% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. GEVA: No Debt )
GEVA' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: No Debt

Equity to Asset 0.94
GEVA's Equity to Asset is ranked higher than
96% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GEVA: 0.94 )
GEVA' s 10-Year Equity to Asset Range
Min: -4.72   Max: 0.96
Current: 0.94

-4.72
0.96
Interest Coverage No Debt
GEVA's Interest Coverage is ranked higher than
89% of the 654 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GEVA: No Debt )
GEVA' s 10-Year Interest Coverage Range
Min: 7.93   Max: 9999.99
Current: No Debt

7.93
9999.99
F-Score: 2
Z-Score: 73.55
M-Score: -3.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -2959.53
GEVA's Operating margin (%) is ranked higher than
53% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. GEVA: -2959.53 )
GEVA' s 10-Year Operating margin (%) Range
Min: -6866.73   Max: 120.8
Current: -2959.53

-6866.73
120.8
Net-margin (%) -2967.47
GEVA's Net-margin (%) is ranked higher than
53% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. GEVA: -2967.47 )
GEVA' s 10-Year Net-margin (%) Range
Min: -7000   Max: 81
Current: -2967.47

-7000
81
ROE (%) -37.27
GEVA's ROE (%) is ranked higher than
70% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. GEVA: -37.27 )
GEVA' s 10-Year ROE (%) Range
Min: -105.21   Max: 52.19
Current: -37.27

-105.21
52.19
ROA (%) -35.46
GEVA's ROA (%) is ranked higher than
67% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. GEVA: -35.46 )
GEVA' s 10-Year ROA (%) Range
Min: -74.33   Max: 32.45
Current: -35.46

-74.33
32.45
ROC (Joel Greenblatt) (%) -716.32
GEVA's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. GEVA: -716.32 )
GEVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2491.51   Max: 320.19
Current: -716.32

-2491.51
320.19
Revenue Growth (3Y)(%) -34.40
GEVA's Revenue Growth (3Y)(%) is ranked higher than
62% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. GEVA: -34.40 )
GEVA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -70.4   Max: 158
Current: -34.4

-70.4
158
EBITDA Growth (3Y)(%) -11.20
GEVA's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 828 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. GEVA: -11.20 )
GEVA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -79.9   Max: 30.9
Current: -11.2

-79.9
30.9
EPS Growth (3Y)(%) -11.80
GEVA's EPS Growth (3Y)(%) is ranked higher than
73% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. GEVA: -11.80 )
GEVA' s 10-Year EPS Growth (3Y)(%) Range
Min: -78.5   Max: 30.5
Current: -11.8

-78.5
30.5
» GEVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

GEVA Guru Trades in Q1 2014

Columbia Wanger 3,217,000 sh (unchged)
Columbia Wanger 3,093,000 sh (-3.85%)
» More
Q2 2014

GEVA Guru Trades in Q2 2014

Columbia Wanger 3,521,000 sh (+13.84%)
» More
Q3 2014

GEVA Guru Trades in Q3 2014

Jim Simons 26,200 sh (New)
Columbia Wanger 3,927,006 sh (+11.53%)
» More
Q4 2014

GEVA Guru Trades in Q4 2014

Columbia Wanger 3,847,094 sh (unchged)
Jim Simons Sold Out
Columbia Wanger 3,847,094 sh (-2.03%)
» More
» Details

Insider Trades

Latest Guru Trades with GEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.70
GEVA's P/B is ranked higher than
59% of the 1612 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. GEVA: 7.70 )
GEVA' s 10-Year P/B Range
Min: 0.76   Max: 17.16
Current: 7.7

0.76
17.16
P/S 545.70
GEVA's P/S is ranked lower than
52% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. GEVA: 545.70 )
GEVA' s 10-Year P/S Range
Min: 1.04   Max: 594.45
Current: 545.7

1.04
594.45
Current Ratio 18.14
GEVA's Current Ratio is ranked higher than
94% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. GEVA: 18.14 )
GEVA' s 10-Year Current Ratio Range
Min: 0.13   Max: 29.94
Current: 18.14

0.13
29.94
Quick Ratio 18.14
GEVA's Quick Ratio is ranked higher than
94% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. GEVA: 18.14 )
GEVA' s 10-Year Quick Ratio Range
Min: 0.13   Max: 29.94
Current: 18.14

0.13
29.94
Days Sales Outstanding 55.44
GEVA's Days Sales Outstanding is ranked higher than
85% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. GEVA: 55.44 )
GEVA' s 10-Year Days Sales Outstanding Range
Min: 0.32   Max: 490.14
Current: 55.44

0.32
490.14

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.60
GEVA's Price/Net Cash is ranked higher than
83% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 107.00 vs. GEVA: 8.60 )
GEVA' s 10-Year Price/Net Cash Range
Min: 2.58   Max: 220.96
Current: 8.6

2.58
220.96
Price/Net Current Asset Value 8.60
GEVA's Price/Net Current Asset Value is ranked higher than
82% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. GEVA: 8.60 )
GEVA' s 10-Year Price/Net Current Asset Value Range
Min: 2.3   Max: 19.34
Current: 8.6

2.3
19.34
Price/Tangible Book 7.70
GEVA's Price/Tangible Book is ranked higher than
72% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. GEVA: 7.70 )
GEVA' s 10-Year Price/Tangible Book Range
Min: 1.01   Max: 19.37
Current: 7.7

1.01
19.37
Price/Median PS Value 35.00
GEVA's Price/Median PS Value is ranked higher than
65% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. GEVA: 35.00 )
GEVA' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 46.72
Current: 35

0.1
46.72
Earnings Yield (Greenblatt) -5.30
GEVA's Earnings Yield (Greenblatt) is ranked higher than
69% of the 1398 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. GEVA: -5.30 )
GEVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -5.3   Max: 3528.7
Current: -5.3

-5.3
3528.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TMS1.Germany,
Synageva BioPharma Corp is incorporated in Delaware in 1993. On November 2, 2011, Trimeris, Inc., a Delaware corporation closed a merger transaction, Reverse Merger with Synageva BioPharma Corp., Pursuant to the Merger Agreement, Private Synageva became a wholly owned subsidiary of Trimeris. As a Reverse Merger, Trimeris changed its name to Synageva BioPharma Corp. The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The Company has several proteins therapeutic in its pipeline, including enzyme replacement therapies for lysosomal storage diseases (LSDs) and protein therapeutic programs for other rare diseases that are at the stage of preclinical development. Its program, sebelipase alfa is a recombinant human lysosomal acid lipase deficiency (LAL Deficiency), currently evaluating in global Phase 3 clinical trials in infants, children and adults with LAL Deficiency. LAL Deficiency is rare autosomal recessive LSD characterized by decreased LAL enzyme activity leading to intracellular accumulation of lipids. This disease leads to medical complications with significant morbidity and early mortality. Sebelipase alfa has been granted orphan designation by the FDA, the EMA, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa has received Fast Track Designation by the FDA, and Breakthrough Therapy designation by the FDA for LAL Deficiency presenting in infants. The Company has not yet received approval to market this product and is not currently commercializing any other products. Sebelipase alfa is a recombinant form of the human LAL enzyme under development as an enzyme replacement therapy for LAL Deficiency. The Company is currently enrolling and dosing Phase 3 Trial of Sebelipase Alfa in Children and Adults with LAL Deficiency. It is also pursuing a development strategy for sebelipase alfa to assess safety and tolerability in a broad population of patients, including infants, children, and adults, and to demonstrate efficacy, safety and tolerability of sebelipase alfa in the treatment of LAL Deficiency. Its potential competitors include large pharmaceutical and biotechnology companies and specialty pharmaceutical companies, academic institutions, government agencies, and research institutions. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its product candidates and future products, are subject to extensive regulation by governmental authorities in the U.S. and other countries.
» More Articles for GEVA

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Synageva BioPharma Submits Kanuma™ (Sebelipase Alfa) Application For LAL Deficiency In Mexico Mar 30 2015
SYNAGEVA BIOPHARMA CORP Financials Mar 05 2015
Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY)... Mar 05 2015
10-K for Synageva BioPharma Corp. Feb 28 2015
Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day... Feb 27 2015
Synageva BioPharma reports 4Q loss Feb 26 2015
Synageva BioPharma reports 4Q loss Feb 26 2015
Synageva Biopharma Corp Earnings Call scheduled for 4:30 pm ET today Feb 26 2015
SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 26 2015
Synageva BioPharma Reports 2014 Full Year Financial Results Feb 26 2015
Q4 2014 Synageva Biopharma Corp Earnings Release - After Market Close Feb 26 2015
Synageva BioPharma To Present At The Cowen and Company Health Care Conference Feb 25 2015
FDA Accepts BLA Filing For Synageva's Kanuma™ (Sebelipase Alfa); Grants Priority Review And... Feb 23 2015
Synageva BioPharma To Host 2014 Fourth Quarter And Full Year Financial Results Conference Call On... Feb 19 2015
Synageva European Patent Issued For Treatment Of LAL Deficiency Feb 18 2015
Synageva BioPharma Announces Presentations At 11th Annual World Symposium Feb 11 2015
SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 09 2015
SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 02 2015
Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog Jan 28 2015
Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For... Jan 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK